



### Introduction:

<b>Sedation:</b>	Reduction of anxiety
<b>Hypnosis:</b>	Induction of sleep
<b>Sedative:</b>	Synonym=anxiolytic, Reduces anxiety and has a calming effect
<b>Hypnotic:</b>	Produces drowsiness, Induces and maintains sleep

### Dose-Responsive Curve for S-H Agents:




### Classification:



### Benzodiazepines:

- > **Short-acting:** Triazolam
- > **Intermediate-acting:** alprazolam, lorazepam, oxazepam, temazepam
- > **Long acting:** pentobarbitone, phenobarbitone, secobarbitone

### Mechanism of Action:



### MOA: Benzodiazepines

**Receptors for BZ present** = Thalamus, limbic structures, cerebral cortex

**BZ receptors =**

- > Part of GABA<sup>A</sup> receptor chloride ion channel macromolecular complex
- > Major GABA<sup>A</sup> receptor isoform
- > Five subunits: 2α1, 2β2, and 1γ2

Benzodiazepines bind between **α1 and γ2 subunits**

Increase the **FREQUENCY** of GABA-mediated chloride ion opening

### MOA: Barbiturates:

- > Depress neural activity in midbrain reticular formation
- > Bind to **α and β subunits of the GABA<sup>A</sup> receptor**
- > Prolong the action of GABA and glycine

Increase the **DURATION** of GABA-mediated chloride ion channel opening

- > may also block glutamate receptors and sodium channels at higher doses

### MOA: Other Agents:

Zolpidem, Zaleplon, Eszopiclone = **not Benzodiazepines**

> Bind to benzodiazepine receptor (BZ1 or ω1)

More selective to GABA<sup>A</sup> isoforms that contain α1 subunits

- Fewer adverse effects than benzodiazepines


- Minimal effects on sleep patterns, less likely to cause dependence

> Increase the **FREQUENCY** of GABA-mediated chloride ion opening

### Effects:

Sedation	Anticonvulsant actions	Tolerance
Hypnosis	Muscle relaxation	Psychological dependence - Compulsive use
Anaesthesia	Medullary depression	Physiological dependence - withdrawal symptoms if drug is discontinued

### CNS Effects:



### Clinical Uses:

- > Anxiety states
- > Sleep disorders
- > Anesthesia
- > Epilepsy
- > Alcohol withdrawal state

### Adverse Effects:

<b>Psychomotor Dysfunction:</b>	Cognitive impairment, decreased psychomotor skills, daytime sedation
<b>Additive CNS Depression:</b>	Alcohol, antihistamines, antipsychotic agents, opioids, tricyclic antidepressants
<b>Overdose:</b>	CVS and respiratory depression, Antidote: Flumazenil

### Pharmacokinetics:

> Most are lipid soluble, absorbed well from GIT

> May cross the placental barrier during pregnancy - may depress neonatal vital functions

> Detectable in breast milk - may exert depressant effects in nursing infant

> Metabolism by hepatic enzymes - renal function = no significant effect on elimination

### Pharmacokinetics:

#### Benzodiazepines:

-Converted to active metabolites with long half-lives

--Potential for accumulation

-Lorazepam and oxazepam do not form active metabolites

-Metabolized mainly by CYP3A4

#### Barbiturates:

-Extensively metabolized

--Except pentobarbital

---Excreted partly unchanged in urine

**Zolpidem:** No active metabolites

#### Drug Interactions:

-Inducers/inhibitors of CYP3A4 interact with sedative hypnotics

--E.g. rifampicin (inducer), ketoconazole, cimetidine (inhibitors)

-Barbiturates induce metabolic enzymes

### Atypical Sedative-Hypnotics:

#### Bupirone:

>Partial agonist at 5-HT<sup>1A</sup> receptors

>Selective anxiolytic effects:

-Minimal CNS depressant effects = No anticonvulsant or muscle relaxation effect

>Minimal tolerance, dependence, and abuse potential

#### Ramelteon, Tasimelteon:

> Melatonin receptor agonists

>Minimal rebound or withdrawal symptoms

>Minimal abuse potential

